Use: Labeled indications
- INDICATIONS AND USAGE: Tobramycin and dexamethasone ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular…
Full indications and usage US FDA label
INDICATIONS AND USAGE: Tobramycin and dexamethasone ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation.
They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye.
The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae.
Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species.
Contraindications
CONTRAINDICATIONS: Epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, and many other viral diseases of the cornea and conjunctiva. Mycobacterial infection of the eye. Fungal diseases of ocular structures. Hypersensitivity to a component of the medication.
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION: One or two drops instilled into the conjunctival sac(s) every four to six hours. During the initial 24 to 48 hours, the dosage may be increased to one or two drops every two (2) hours. Frequency should be decreased gradually as warranted by improvement in clinical signs. Care should be taken not to discontinue therapy prematurely. Not more than 20 mL should be prescribed initially and the prescription should not be refilled without further evaluation as outlined in PRECAUTIONS above.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
Pediatric Use: Safety and effectiveness in pediatric patients below the age of 2 years have not been established.
Dosing: Older adult
Geriatric use (US label) US FDA label
Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger patients.
Dosage forms
Philippines
- Per ml ophthalmic suspension: 3 mg/1 mg
- Per ml sterile ophthalmic suspension: 3 mg/1 mg
- Per ml ophtalmic suspension: 3 mg/1 mg
- Per ml ophthalmic solution: 3 mg/1 mg
- Per ml sterile ophthalmic solution: 3 mg/1 mg
- Per g sterile ophthalmic ointment: 3 mg/1 mg
- Per ml: 3 mg/1 mg
- Per ml opthalmic solution: 3 mg/1 mg
- Per ml opthalmic suspension: 3 mg/1 mg
- Per ml sterile ophthalmic ointment: 1 mg/3 mg
and 1 more forms; see the products table.
Registered products in the Philippines
55 products registered with the Food and Drug Administration (FDA) Philippines list Dexamethasone + Tobramycin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products55
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AbradexTobramycin (as sulfate) + Dexamethasone (as sodium phosphate) | 3 mg/1 mg (0.3% 0.1% w/v) per mL Sterile Ophthalmic Suspension (Eye Drops)Opaque plastic bottle x 5 mL with nozzle and cap (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | Afree Pharmaceutical Distribution Corp. | DRP-14088 | Jun 20, 2028 | |
AccetodexTobramycin + Dexamethasone | 3mg/1mg per mL Ophthalmic Suspension (Eye Drops)10 mL White HDPE Dropper Bottle with Nozzle and Cap x 5 mL (Net content) Box of 1's) | Rx | Opal Laboratories (Pvt.) Limited.Pakistan | Accesspoint International Trading, IncImporter: Accesspoint International Trading, Inc. | DRP-14892 | Feb 1, 2029 | |
AdtoberexTobramycin (as sulfate) + Dexamethasone (as sodium phosphate) | 3 mg /1 mg (0.3 % w/v / 0.1 % w/v) per mL Ophthalmic Suspension (Drops)10 mL White LDPE Bottle with Nozzle and Cap x 5 mL (net content) (Box of 1's) | Rx | Kilitch Drugs (India) Ltd.India | Sensomed Phils., Inc.Importer: Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-11458-01 | Mar 15, 2027 | |
Agua Dex-TTobramycin (as sulfate) + Dexamethasone (as sodium phosphate) | 3 mg/1 mg (0.3% w/v/0.1% w/v) per mL Ophthalmic Suspension (Drops)10 mL White LDPE Bottle with Nozzle and Cap x 5 mL (net content) (Box of 1's) | Rx | Kilitch Drugs (India) Ltd.India | Agua Visions TradingImporter: Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-11458-02 | Mar 15, 2027 | |
AguadexaTobramycin (as sulfate) + Dexamethasone (as sodium phosphate) | 3 mg / 1 mg (0.3 % /0.1 % w/v) per mL Sterile Ophthalmic Suspension (Eye Drops)Opaque plastic bottle x 5 mL with nozzle and cap (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | Agua Visions TradingImporter: Afree Pharmaceutical Distribution Corp. | DRP-14088-04 | Jun 20, 2028 | |
ANTILOUPETobramycin + Dexamethasone | 3 mg/1 mg per mL Ophthalmic SuspensionLDPE Plastic Eye Dropper Bottle x 5 mL Box of 1's | Rx | Ashford Pharmaceutical Laboratories, Inc.Philippines | PNJ Pharma EnterpriseTrader: Medilife Pharma, Inc. | DRP-424-07 | Feb 5, 2027 | |
AxatobTobramycin (as sulfate) + Dexamethasone phosphate (as sodium) | 3 mg/1 mg per mL (0.3% w/v/0.1% w/v) Sterile Ophthalmic Solution (Eye Drops)LDPE Bottle x 5 mL (Box of 1's) | Rx | Axa Parenterals LimitedIndia | Brady Pharma Inc. | DRP-9785 | Jun 7, 2031 | |
BrametTobramycin + Dexamethasone | 3 mg/1 mg per mL Opthalmic SolutionLDPE vial x 10 mL (Box of 1's) | Rx | East African (India) OverseasIndia | Airlife International Trading Corporation | DRP-18054 | Apr 30, 2031 | |
CelodexTobramycin + Dexamethasone | 3 mg /1 mg per mL Ophthalmic Suspension (Eye Drops)10 mL White HDPE Dropper Bottle with Nozzle and Cap x 5 mL (Net content) (Box of 1's) | Rx | Opal Laboratories (Pvt.) LimitedPakistan | GCM Pharmaceutical DealerImporter: Accesspoint International Trading, Inc. | DRP-14892-04 | Feb 1, 2029 | |
CindexTobramycin (as sulfate) + Dexamethasone (as sodium phosphate) | 3 mg/1 mg (0.3%/0.1% w/v) per mL Sterile Ophthalmic Suspension (Eye Drops)Opaque plastic bottle x 5 mL with nozzle and cap (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | Victorious King Pharmaceutical and Medical Supplies Inc.Importer: Afree Pharmaceutical Distribution Corp. | DRP-14088-11 | Jun 20, 2028 | |
CombidarTobramycin (as sulfate) + Dexamethasone (as sodium phosphate) | 3 mg / 1 mg (0.3 % / 0.1 % w/v) per mL Sterile Ophthalmic Suspension (Eye Drops)Opaque plastic bottle x 5 mL with nozzle and cap (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | Belvadar Pharmaceuticals Inc.Importer: Afree Pharmaceutical Distribution Corp. | DRP-14088-01 | Jun 20, 2028 | |
DexatobrinDexamethasone + Tobramycin | 1 mg/3 mg per mL (0.1 % 0.3% w/v) Sterile Ophthalmic OintmentAluminum Collapsible tube with HDPE screw cap x 5 g (Box 1's) | Rx | Egyptian International Pharmaceutical Industries Co.,Egypt | Ambica International Corporation.Importer: Ambica International Corporation | DRP-15087 | Apr 18, 2029 | |
DikshaminTobramycin (as sulfate) + Dexamethasone (as sodium phosphate) | 3 mg/1 mg (0.3%/0.1% w/v) per mL Sterile Ophthalmic Suspension (Eye Drops)Opaque platsic bottle x 5 mL with nozzle and cap (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | Bliss Pharma Distribution and Consultancy Corp.Importer: Afree Pharmaceutical Distribution Corp. | DRP-14088-07 | Jun 20, 2028 | |
DuocomTobramycin + Dexamethasone | 3 mg / 1 mg per mL Ophthalmic Suspension (Drops)5 mL net content in 10 mL HDPE Pilfer-guard eye dropper plastic bottle (Box of 1's) | Rx | EL Laboratories, Inc.Philippines | Trader: Vista Pharma, Inc. | DR-XY31241 | May 3, 2027 | |
EyedexTobramycin (as sulfate) + Dexamethasone (as sodium phosphate) | 3 mg/1 mg (0.3%/0.1% w/v) per mL Sterile Ophthalmic Suspension (Eye Drops)Opaque plastic bottle x 5mL with nozzle and cap (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | TGP Pharma Inc.Importer: Afree Pharmaceutical Distribution Corp. | DRP-14088-08 | Jun 20, 2028 | |
I Care DuoTobramycin (as sulfate) + Dexamethasone (as sodium phosphate) | 3 mg/1 mg per mL (0.3 % w/v) Ophtalmic SuspensionWhite plastic bottle x 5 mL and 10 mL with LDPE dropper and HDPE screw cap (Box of 1's) | Rx | Med Biopharm Pvt. Ltd.India | Medvybe Pharmaceutical TradingImporter: Pors Pharma Trading | DRP-17110-01 | Jan 27, 2030 | |
KodexTobramycin + Dexamethasone | 3mg/1mg per mL Ophthalmic Suspension (Eye Drops)10 mL White HDPE Dropper Bottle with Nozzle and Cap x 5 mL (Net content) (Box of 1's) | Rx | Opal Laboratories (Pvt.) LimitedPakistan | Kodapharm Med Corp.Importer: Accesspoint International Trading Inc. | DRP-14892-01 | Feb 1, 2029 | |
Lumi-DuoTobramycin + Dexamethasone | 3 mg/1mg per mL Ophthalmic Suspension (Eye Drops)10 mL White HDPE Dropper Bottle with Nozzle and Cap x 5 mL (Net Content) (Box of 1's) | Rx | Opal Laboratories (Pvt.) LimitedPakistan | Visionaire Pharmaceutical Products TradingImporter: Accesspoint International Trading Inc. | DRP-14892-05 | Feb 1, 2029 | |
Mycinidin PlusTobramycin (as sulfate) + Dexamethasone (as sodium phosphate) | 3 mg/1 mg (0.3%/0.1% w/v) per mL Sterile Ophthalmic Suspension (Eye Drops)Opaque plastic bottle x 5 mL with nozzle and cap (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | Medchoice Vision Care, Inc.Importer: Afree Pharmaceutical Distribution Corp. | DRP-14088-12 | Jun 20, 2028 | |
NoneTobramycin (as sulfate) + Dexamethasone (as sodium phosphate) | 3 mg /1 mg (0.3% / 0.1% w/v) per mL Sterile Ophthalmic Suspension (Eye Drops)Opaque plastic bottle x 5 mL with nozzle and cap (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | Bliss Pharma Distribution and Consultancy Corp.Importer: Afree Pharmaceutical Distribution Corp. | DRP-14088-06 | Jun 20, 2028 | |
NoneTobramycin (as sulfate) + Dexamethasone (as sodium phosphate) | 3 mg/1 mg (0.3% / 0.1% w/v) per mL Sterile Ophthalmic Suspension (Eye Drops)Opaque plastic bottle x 5 mL with nozzle and cap (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | Bliss Pharma Distribution and Consultancy Corp.Importer: Afree Pharmaceutical Distribution Corp. | DRP-14088-02 | Jun 20, 2028 | |
NoneTobramycin (as sulfate) + Dexamethasone (as sodium phosphate) | 3 mg/1 mg (0.3%/0.1% w/v) per mL Sterile Ophthalmic Suspension (Eye Drops)Opaque plastic bottle x 5 mL with nozzle and cap (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | Merzeal Marketing OPCImporter: Afree Pharmaceutical Distribution Corp. | DRP-14088-05 | Jun 20, 2028 | |
NoneTobramycin (as sulfate) + Dexamethasone (as sodium phosphate) | 3 mg/1 mg per mL (0.3%/0.1% w/v) Sterile Ophthalmic Suspension (Eye Drops)Opaque plastic bottle x 5 mL with nozzle and cap (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | Reta DrugImporter: Afree Pharmaceutical Distribution Corp. | DRP-14088-13 | Jun 20, 2028 | |
NoneTobramycin + Dexamethasone | 3 mg/1 mg per mL Ophthalmic SuspensionLDPE Plastic Eye Dropper Bottle x 5 mL (Box of 1's) | Rx | Ashford Pharmaceutical Laboratories, Inc.Philippines | Celsus Pharmaceuticals Phils., Inc.Trader: Medilife Pharma, Inc. | DRP-424-08 | Feb 5, 2027 | |
NoneTobramycin + Dexamethasone | 3 mg/1mg per mL Ophthalmic Suspension (Eye Drops)10 mL White HDPE Dropper Bottle with Nozzle and Cap x 5 mL (Net Content) (Box of 1's) | Rx | Opal Laboratories (Pvt.) LimitedPakistan | Reta DrugImporter: Accesspoint International Trading Inc. | DRP-14892-02 | Feb 1, 2029 | |
OBREXTobramycin + Dexamethasone | 3 mg/1 mg per mL Ophthalmic Suspension | Rx | Ashford Pharmaceutical Laboratories, Inc. | JNJ Pharma EnterprisesTrader: Medilife Pharma, Inc. | DRP-424-05 | Feb 5, 2027 | |
ObrexinTobramycin (as sulfate) + Dexamethasone (as sodium phosphate) | 3 mg/1 mg (0.3%/0.1% w/v) per mL Sterile Ophthalmic Suspension (Eye Drops)Opaque plastic bottle x 5 mL with nozzle and cap (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | JNJ Pharma EnterprisesImporter: Afree Pharmaceutical Distribution Corp. | DRP-14088-10 | Jun 20, 2028 | |
OcumydexTobramycin + Dexamethasone | 3 mg/1 mg per mL (0.3%/0.1% w/v) Ophthalmic Suspension (Eye Drops)5 mL white LDPE bottle with LDPE dropper and HDPE/LDPE cap (Box of 1's) | Rx | Rafarm SAGreece | UNILAB, Inc. | DRP-17147 | Oct 7, 2030 | |
OPIDEXTobramycin + Dexamethasone | 3 mg/1 mg per mL Ophthalmic Suspension (Eye Drops)LDPE Bottle x 6 mL (Box of 1's) | Rx | Daewoo Pharm. Co., Ltd.Republic of Korea | Starpharm, Inc. | DR-XY45228 | Mar 31, 2031 | |
OpidexTobramycin + Dexamethasone | 3 mg/1 mg per mL Ophthalmic Suspension (Eye Drops)LDPE Bottle x 6 mL (Box of 1's) | Rx | Daewoo Pharm. Co., Ltd.Republic of Korea | Starpharm, Inc. | DRP-17717 | Mar 31, 2031 | |
Orbidex TTobramycin + Dexamethasone (as sodium phosphate) | 3mg/1mg per mL (0.3%/ 0.1% w/v) Sterile Ophthalmic Solution (Eye Drops)White Opaque PE Plastic Dropper Bottle with PE Nozzle and HDPE Cap x 5mL (Box of 1's) | Rx | POPULAR PHARMACEUTICALS LTD.Bangladesh | HEKA HEALTH INTERNATIONAL CORP. | DR-XY43433 | May 20, 2029 | |
RamtrexTobramycin + Dexamethasone | 3 mg/ 1 mg per mL Ophthalmic SuspensionLDPE Plastic Eye Dropper Bottle x 5 mL (Box of 1's) | Rx | Ashford Pharmaceutical Laboratories, Inc.Philippines | Trader: Medilife Pharma, Inc. | DRP-424 | Feb 5, 2032 | |
ReladexTobramycin (as sulfate) + Dexamethasone (as sodium phosphate) | 3 mg/1 mg (0.3% w/v / 0.1% w/v) per mL Ophthalmic Suspension (Drops)10 mL White LDPE Bottle with Nozzle and Cap x 5 m L (net content) (Box of 1's) | Rx | Kilitch Drugs (India) Ltd.India | Visionaire Pharmaceutical Products TradingImporter: Nelpa Lifesciences Pvt. Ltd.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-11458-03 | Mar 15, 2027 | |
Tob-dexTobramycin + Dexamethasone | Ophthalmic Solution (Eye Drops) 3 mg/1 mg per mL (0.3% w/v 0.1% w/v)LDPE White Opaque Dropper Bottle x 5 mL Box of 1's | Rx | AurolabIndia | Brady Pharma Inc. | DRP-4020 | Sep 22, 2031 | |
TobarenTobramycin + Dexamethasone | 3 mg/1 mg per mL (0.3% 0.1% w/v) Sterile Ophthalmic Suspension (Eye Drops)LDPE Plastic Bottle with LDPE inner cap and HDPE outer cap x 5mL (Box of 1) | Rx | Samchundang Pharm Co., Ltd.Republic of Korea | I-Senz Medical Inc.Importer: I-Senz Medical Inc | DRP-8919 | Jun 24, 2031 | |
Tobdex FreeTobramycin (as sulfate) + Dexamethasone (as sodium phosphate) | 3 mg/1 mg (0.3% w/v / 0.1% w/v) per mL Sterile Ophthalmic Suspension (Eye Drops)Opaque plastic bottle x 5 mL with nozzle and cap (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | Qure Corp.Importer: Afree Pharmaceutical Distribution Corp. | DRP-14088-03 | Jun 20, 2028 | |
Tobracare-DTobramycin + Dexamethasone | 3 mg/1 mg per mL Ophtalmic Suspension (Eye Drops)10 mL White HDPE Dropper Bottle with Nozzle and Cap x 5 mL (Net Content) (Box of 1's) | Rx | Opal Laboratories (Pvt.) LimitedPakistan | Savelink Pharma And Trading Co.Importer: Accesspoint International Trading Inc. | DRP-14892-03 | Feb 1, 2029 | |
Tobracid-DMTobramycin (as sulfate) + Dexamethasone (as sodium phosphate) | 3mg/1mg per mL Ophthalmic SolutionLDPE Plastic Bottle x 10 mL (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | Ensight Pharmaceuticals Inc.Trader: Entod Pharmaceuticals Ltd. | DRP-13125 | Dec 5, 2027 | |
TobradeporsTobramycin (as sulfate) + Dexamethasone (as sodium phosphate) | 3 mg/1 mg per mL (0.3 % w/v) Ophtalmic SuspensionWhite plastic bottle x 5 mL and 10 mL with LDPE dropper and HDPE screw cap (Box of 1's) | Rx | Med Biopharm Pvt. Ltd.India | Pors Pharma Trading | DRP-17110 | Jan 27, 2030 | |
TobradeporsTobramycin (as sulfate) + Dexamethasone (as sodium. phosphate) | 3 mg/1 mg per mL (0.3% w/v) Ophthalmic SuspensionWhite plastic bottle x 5 mL and 10 mL with LDPE dropper and HDPE screw cap (Box of 1's) | Rx | Med Biopharm Pvt. Ltd.India | Pors Pharma Trading | DR-XY49318 | Jan 27, 2030 | |
TobradexTobramycin + Dexamethasone | 3 mg/1 mg per g Sterile Ophthalmic OintmentAluminum Tube x 3.5 g | Rx | Alcon-Couvreur NVBelgium | Importer: Novartis Healthcare Philippines, Inc. | DR-XY15352 | Feb 4, 2027 | |
TobradexTobramycin +Dexamethasone | 3 mg/1 mg per mL Sterile Ophthalmic SuspensionWhite low density polyethylene droptainer x 5 mL | Rx | Alcon-Couvreur NVBelgium | Importer: Novartis Healthcare Philippines, Inc. | DR-XY14481 | Feb 4, 2027 | |
TobrametTobramycin (as sulfate) + Dexamethasone | 3 mg/1 mg per mL (0.3% /0.1% w/v) Ophthalmic SuspensionSterile Opaque Plastic Bottle x 5 mL (Box of 1 bottle) | Rx | Indiana OphthalmicsIndia | Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd. | DRP-15071 | Apr 4, 2029 | |
Tobrasafe-DTobramycin (as sulfate) + Dexamethasone (as sodium phosphate) | 3 mg/1 mg (0.3 % / 0.1 % w/v) per mL Sterile Ophthalmic Suspension (Eye Drops)Opaque plastic bottle x 5 mL with nozzle and cap (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | Preventia Healthcare Inc.Importer: Afree Pharmaceutical Distribution Corp. | DRP-14088-14 | Jun 20, 2028 | |
Tobrasaph-DexTobramycin (as sulfate) + Dexamethasone (as sodium phosphate) | 3 mg/1 mg (0.3% w/v / 0.1 % w/v) per mL Ophthalmic Suspension (Drops)10 mL White LDPE Bottle with Nozzle and Cap x 5 mL (net content) (Box of 1's) | Rx | Kilitch Drugs (India) Ltd.India | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-11458 | Mar 15, 2027 | |
TobrasonTobramycin + Dexamethasone | 3 mg/ 1 mg per mL Ophthalmic Suspension (Eye Drops)Plastic squeeze bottle x 5 mL (Box of 1's) | Rx | Ashford Pharmaceutical Laboratories, Inc.Philippines | Trader: Pharmabiz Solutions, Inc. | DRP-2171 | Feb 9, 2037 | |
Tobraspar-PlusTobramycin (as sulfate) + Dexamethasone (as Sodium phosphate) | 3 mg /1 mg (0.3 %/0.1% w/v) per mL Opthalmic Suspension (Eye Drops)10 ml-Capacity White LDPE Bottle with Nozzle Sealed With HDPE Cap x 5 mL (Net content) (Box of 1's) | Rx | Alwin DMD PharmaceuticalsIndia | Aspar Pharmaceutical Inc. | DRP-18355 | Jun 18, 2031 | |
Tobrazin PlusTobramycin (as sulfate) + Dexamethasone sodium phosphate | 3 mg/1 mg (0.3% / 0.1%) per mL Ophthalmic Solution (Drops)White HDPE vial x 10 mL (Box of 1's) | Rx | Scott-Edil Pharmacia Ltd.India | Greencore Pharma Inc. | DRP-15855 | Sep 25, 2029 | |
TobridixTobramycin (as sulfate) + Dexamethasone (as sodium phosphate) | 3 mg/1 mg (0.3% / 0.1% w/v) per mL Sterile Ophthalmic Suspension (Eye Drops)Opaque plastic bottle x 5 mL with nozzle and cap (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | Bliss Pharma Distribution and Consultancy Corp.Importer: Afree Pharmaceutical Distribution Corp. | DRP-14088-15 | Jun 20, 2028 | |
Tobyn-DTobramycin (As Sulfate) + Dexamethasone (As Sodium Phosphate) | 3 mg / 1 mg (0.3% / 0.1%) per mL Ophthalmic Solution (Drops)10 mL in 15 mL capacity LDPE White Opaque Vial with white colour, ABS material polystyrene nozzle and white colour pilfer proof ring cap Box of 1's | Rx | Nitin Lifesciences Ltd.India | Seapharma International, Inc. | DRP-5912 | Dec 19, 2029 | |
TodeloupeTobramycin (as sulfate) + Dexamethasone | 3mg/1mg per mL (0.3%/0.1% w/v) Ophthalmic SuspensionSterile Opaque Plastic Bottle x 5 mL (Box of 1 bottle) | Rx | Indiana OphthalmicsIndia | PNJ Pharma EnterpriseImporter: Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd. | DRP-15071-01 | Apr 4, 2029 | |
TodexCareTobramycin + Dexamethasone | 3 mg/1 mg per mL Ophthalmic SuspensionLDPE Plastic Eye Dropper Bottle x 5 mL (Box of 1's) | Rx | Ashford Pharmaceutical Laboratories, Inc.Philippines | Sensorycare Pharma Co.Trader: Medilife Pharma, Inc. | DRP-424-09 | Feb 5, 2027 | |
UnbrandedTobramycin + Dexamethasone | 3 mg/1mg per mL (0.3% w/v) Sterile SuspensionWhite LDPE Plastic Bottle x 5mL (Box of 1's) | Rx | E. L. Laboratories, Inc.Philippines | Trader: Celsus Pharmaceuticals Phils., Inc. | DR-XY30961 | Aug 5, 2031 | |
Zartob DMTobramycin (as sulfate) + Dexamethasone (as sodium phosphate) | 3 mg/1 mg (0.3%/0.1% w/v) per mL Sterile Ophthalmic Suspension (Eye Drops)Opaque plastic bottle x 5 mL with nozzle and cap (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | Optha Pharma Traders Inc.Importer: Afree Pharmaceutical Distribution Corp. | DRP-14088-09 | Jun 20, 2028 | |
ZytodexTobramycin + Dexamethasone | 3 mg / 1 mg per mL Ophthalmic Suspension (Eye Drops)Plastic Dropper Tip Squeeze Bottle x 5 mL (Box of 1 ’s) | Rx | The Schazoo Pharmaceutical Laboratories (Pvt) Ltd.Pakistan | Zuneca Incorporated | DR-XY36786 | Oct 12, 2029 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNINGS: FOR EYE USE ONLY. NOT FOR INJECTION INTO THE EYE. Sensitivity to topically applied aminoglycosides may occur in some patients. Severity of hypersensitivity reactions may vary from local effects to generalized reactions, such as erythema, itching, urticaria, skin rash, anaphylaxis, anaphylactoid reactions, or bullous reactions.
If a sensitivity reaction does occur, discontinue use. Prolonged use of steroids may result in glaucoma, with damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation. Intraocular pressure (IOP) should be routinely monitored even though it may be difficult in pediatric patients and uncooperative patients.
Prolonged use may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions and parasitic infections of the eye, steroids may mask infection or enhance existing infection. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids.
Adverse reactions
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS: Adverse reactions have occurred with steroid/anti-infective combination drugs which can be attributed to the steroid component, the anti-infective component, or the combination. Exact incidence figures are not available. The most frequent adverse reactions to topical ocular tobramycin (tobramycin ophthalmic solution 0.3%) are hypersensitivity and localized ocular toxicity, including lid itching and swelling, and conjunctival erythema.
These reactions occur in less than 4% of patients. The reactions due to the steroid component are: elevation of IOP with possible development of glaucoma, and infrequent optic nerve damage; posterior subcapsular cataract formation; and delayed wound healing. Secondary Infection: The development of secondary infection has occurred after use of combinations containing steroids and antimicrobials.
Fungal infections of the cornea are particularly prone to develop coincidentally with long-term applications of steroids. The possibility of fungal invasion must be considered in any persistent corneal ulceration where steroid treatment has been used. Secondary bacterial ocular infection following suppression of host responses also occurs.
Postmarketing Experience: Additional adverse reactions identified from postmarketing use include anaphylactic reaction, erythema multiforme. The following additional adverse reactions have been reported with the individual components listed below: Dexamethasone: Cushing’s syndrome and adrenal suppression may occur after use of dexamethasone in excess of the listed dosing instructions in predisposed patients, including children and patients treated with CYP3A4 inhibitors.
Aminoglycosides: Neurotoxicity, ototoxicity, and nephrotoxicity have occurred in patients receiving systemic aminoglycoside therapy. Aminoglycosides may aggravate muscle weakness in patients with known or suspected neuromuscular disorders, such as myasthenia gravis or Parkinson’s disease, because of their potential effect on neuromuscular function.
Pregnancy considerations
Pregnancy (US label) US FDA label
Pregnancy: Corticosteroids have been found to be teratogenic in animal studies. Ocular administration of 0.1% dexamethasone resulted in 15.6% and 32.3% incidence of fetal anomalies in two groups of pregnant rabbits. Fetal growth retardation and increased mortality rates have been observed in rats with chronic dexamethasone therapy.
Reproduction studies have been performed in rats and rabbits with tobramycin at doses up to 100 mg/kg/day parenterally and have revealed no evidence of impaired fertility or harm to the fetus. There are no adequate and well-controlled studies in pregnant women. However, prolonged or repeated corticoid use during pregnancy has been associated with an increased risk of intra-uterine growth retardation.
Tobramycin and dexamethasone ophthalmic suspension should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be observed carefully for signs of hypoadrenalism.
Breastfeeding considerations
Lactation (US label) US FDA label
Nursing Mothers: Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when tobramycin and dexamethasone ophthalmic suspension is administered to a nursing woman.
Pharmacokinetics
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY: Corticoids suppress the inflammatory response to a variety of agents and they probably delay or slow healing. Since corticoids may inhibit the body's defense mechanism against infection, a concomitant antimicrobial drug may be used when this inhibition is considered to be clinically significant. Dexamethasone is a potent corticoid.
The antibiotic component in the combination (tobramycin) is included to provide action against susceptible organisms. In vitro studies have demonstrated that tobramycin is active against susceptible strains of the following microorganisms: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains.
Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae. Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species.
No data are available on the extent of systemic absorption from tobramycin and dexamethasone ophthalmic suspension; however, it is known that some systemic absorption can occur with ocularly applied drugs.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Tobramycin + Dexamethasone Eye Drops 0.3% + 0.1%, 5 mL Bottle | ₱112.32–₱230.00Reference ₱168.00 | per bottle | DPRI procurement range |
| Tobramycin + Dexamethasone Eye Ointment 0.3% + 0.1%, 3.5 g Tube | ₱190.00–₱520.68Reference ₱190.00 | per tube | DPRI procurement range |
| 0.3% + 0.1% ophthalmic drop suspension in 5 mL bottle | ₱164.50 | per bottle | PhilHealth GAMOT fixed fee |
| 0.3% + 0.1% ophthalmic ointment in 3.5 g tube | ₱491.00 | per tube | PhilHealth GAMOT fixed fee |
PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf, as of October 13, 2026
Formulary and coverage
| Philippine National Formulary | Listed as Tobramycin + Dexamethasone |
| PNF listing | Eye Drops Suspension: 0.3% + 0.1%, 5 mL bottle Eye Ointment: |
| PNF listing | Eye Drops Suspension: 0.3% + 0.1%, 3.5 g tube |
| PhilHealth GAMOT | Yes (listed since October 13, 2026) |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Tobramycin and Dexamethasone · Sandoz Inc [US FDA-approved label, version 12, April 7, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05fd0c36-39b4-4a43-8490-eb8dfc0920ae
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .